지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 668 - 675 (8page)
이용수
초록· 키워드
오류제보하기
Background: Drug survival, defined as the time until discontinuation, is a parameter reflecting real-world therapeutic effectiveness. Few studies have examined the influence of economic factors on the drug survival of biologic agents for psoriasis, particularly in Asian countries. Objective: To determine the drug survival for ustekinumab in real-life settings and investigate the factors affecting drug survival for psoriasis patients in Korea. Methods: We evaluated 98 psoriasis patients who were treated with ustekinumab at a single center. We analyzed the efficacy and drug survival of ustekinumab. Cox proportional hazard analysis and competing risk regression analysis were performed to reveal the factors affecting the drug survival of ustekinumab. Results: The overall mean drug survival was 1,596 days (95% confidence interval [CI], 904∼2,288). Among the 39 cessations of ustekinumab treatment, 9 (23.1%) patients discontinued treatment after experiencing satisfactory results. Multivariate Cox proportional hazard analysis revealed that paying on patients’ own expense was the major predictor for the discontinuation of ustekinumab (hazard ratio [HR], 9.696; 95% CI, 4.088∼22.998). Competing risk regression analysis modeling of discontinuation because of factors other than satisfaction of an event also revealed that ustekinumab treatment at the patient’s expense (HR, 4.138; 95% CI, 1.684∼ 10.168) was a predictor of discontinuation rather than satisfaction. Conclusion: The results of our study revealed that the cost of biologics treatment affects the drug survival of ustekinumab and suggested that economic factors affect the drug survival of ustekinumab treatment in Korea.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
최종원 / 2017 / The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice / Annals of Dermatology 29(1):55~60
Ramirez-Fort MK / 2013 / Continuous versus intermittent therapy for moderate-to-severe psoriasis / Clin Exp Rheumatol 31:S63~S70
Kimball AB / 2012 / Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis:results from the PHOENIX 1 trial through up to 3 years / Br J Dermatol 166:861~872
Vilarrasa E / 2016 / ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice / J Am Acad Dermatol 74:1066~1072
Shalom G / 2017 / Biologic drug survival in Israeli psoriasis patients / J Am Acad Dermatol 76:662~669.e1
Ramirez-Fort MK / 2013 / Continuous versus intermittent therapy for moderate-to-severe psoriasis / Clin Exp Rheumatol 31:S63~S70
Kimball AB / 2012 / Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis:results from the PHOENIX 1 trial through up to 3 years / Br J Dermatol 166:861~872
Vilarrasa E / 2016 / ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice / J Am Acad Dermatol 74:1066~1072
Shalom G / 2017 / Biologic drug survival in Israeli psoriasis patients / J Am Acad Dermatol 76:662~669.e1
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Paradoxical Flare of Psoriasis after Ustekinumab Therapy
Annals of Dermatology
2017 .01
-
Bullous Wells Syndrome Induced by Ustekinumab
Annals of Dermatology
2023 .05
-
Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
Annals of Dermatology
2016 .01
-
Ustekinumab과 Guselkumab에 치료저항성을 보인 건선 1예
대한건선학회지
2019 .01
-
The First Case of Ustekinumab-Associated Hair Repigmentation and a Proposed Mechanism of Action
Annals of Dermatology
2021 .01
-
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Journal of Korean Medical Science
2022 .04
-
Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab
Annals of Dermatology
2018 .01
-
건선 환자에서 생물학적제제 투여 중 재활성화된 잠복결핵 1예
대한건선학회지
2021 .12
-
Ustekinumab으로 성공적으로 치료한 뱀독에 의한 홍색피부건선 1예
대한건선학회지
2020 .01
-
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies
Intestinal research
2017 .01
-
어린선과 동반된 건선을 Ustekinumab으로 치료한 1예
대한건선학회지
2021 .12
-
Risk Factors for poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis in south korea
Hanyang Medical Reviews
2016 .01
-
The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
Annals of Dermatology
2016 .01
-
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Intestinal research
2024 .07
-
Early Improvement and Marriage Are Determinants of the 12-Month Treatment Outcome of Paroxetine in Outpatients with Panic Disorder
Clinical Psychopharmacology and Neuroscience
2017 .01
-
Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder
PSYCHIATRY INVESTIGATION
2016 .01
-
Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan
PSYCHIATRY INVESTIGATION
2021 .01
-
Development of Individual Survival Estimating Program for Cancer Patients’ Management
Healthcare Informatics Research
2015 .01
-
Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
Annals of Dermatology
2018 .01
-
염증장질환의 치료: 생물학적제제 및 새로운 치료법을 중심으로
대한의사협회지
2021 .09
이 논문의 저자 정보
최근 본 자료
댓글(0)
0